XtalPi raises $115M from Hong Kong IPO to expand AI drug R&D services
Chinese AI drug discovery company XtalPi has landed on the Hong Kong stock exchange after nearly $115 million ($896.13 million HKD) from an IPO. XtalPi, which is listing under the name QuantumPharm,...
View ArticleClik here to view.
Bill Haney gives up CEO post at Skyhawk, becomes chairman; Bayer parts ways...
Bill Haney → Bill Haney has helped Skyhawk Therapeutics stand out in the wave of biotechs looking to drug RNA, taking over from fellow co-founder Kathleen McCarthy early in its history and engineering...
View Article#ADA24: Innovent details Phase 3 weight loss data from Lilly-partnered GLP-1...
Innovent Biologics has lifted the curtain on late-stage data from its next-generation “double-G” drug in overweight or obese Chinese patients after the company teased in January that the trial...
View Article#EHA24: Roche details overall survival data on bispecific antibody Columvi
Roche released detailed data at the European Hematology Association congress for its CD20xCD3 bispecific antibody Columvi in earlier lines of large B cell lymphoma, showing just how much the drug...
View ArticleStephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan...
Over a year and a half since its inception, JP Morgan’s life sciences investment arm has closed its first biotech venture capital fund with over $500 million. JP Morgan Life Sciences Private Capital...
View ArticleTakeda signs option deal for TKI inhibitor; Enveda's $55M raise
Plus, news about IN8bio, Rezolute, BeiGene and NewBridge: Takeda, Ascentage ink option deal: The deal involves a compound called olverembatinib, which Takeda described as an oral BCR-ABL TKI inhibitor...
View ArticleAutoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling...
In 30 patients with a number of autoimmune conditions who received Kyverna Therapeutics’ CAR-T cell therapy, 21 were able to stop taking their immune disease medications. The results mark one of the...
View ArticleClik here to view.
Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine
The Biomedical Advanced Research and Development Authority (BARDA) has granted up to $453 million to Vaxart to revive its work on an oral Covid-19 vaccine, backing a technology that had seemingly...
View ArticleRare pediatric disease vouchers face uncertain future after September
Congress has until the end of September to reauthorize a voucher program that’s meant to incentivize new drug development for rare pediatric diseases. But the program faces a tough congressional...
View ArticleEnding 'product hopping' and other patent changes could save US $3B over a...
The Congressional Budget Office predicted that a patent reform bill introduced last year could result in federal savings of more than $3 billion over the next 10 years. The Affordable Prescriptions for...
View ArticleClik here to view.
FDA asks Covid-19 vaccine makers to instead target KP.2 strain for fall season
The FDA is directing Covid-19 vaccine manufacturers to update their formulations to target the KP.2 strain of the virus, citing higher circulation levels of that strain in recent weeks. Last week, the...
View ArticleBIO CEO’s patriotic pivot; Step forward for Lilly’s Alzheimer’s drug;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleGilead cancer drug magrolimab showed worrying trends around death
A Gilead cancer drug whose developments have essentially been halted not only failed to improve survival odds for blood cancer patients but also came with worrying safety risks — including a higher...
View ArticleWith new data, AstraZeneca makes the case for its BTK inhibitor in a...
Combined with chemotherapy and immunotherapy, AstraZeneca’s Calquence reduced the risk of disease progression or death by 27% compared to placebo and chemoimmunotherapy in first-line mantle cell...
View ArticleNurix’s protein degrader overcomes resistance to BTK mutations in small...
Preliminary results from a small study of heavily treated patients with blood cancer suggest that an experimental protein degrader, which removes problematic proteins instead of just inhibiting them,...
View ArticleClik here to view.
Updated: Takeda’s Ovid-licensed drug fails two Phase 3 epilepsy studies
Takeda’s enzyme therapy soticlestat, which aims to balance brain cholesterol and reduce seizures, failed two Phase 3 trials in certain forms of epilepsy. Monday’s double whammy throws cold water on...
View ArticleClik here to view.
Elion Therapeutics raises $81M Series B for antifungal treatment
Elion Therapeutics, a biotech focused on invasive fungal infections, has raised $81 million in a Series B funding round for its early-stage candidate, it announced Monday morning. The candidate, a...
View ArticleIt’s time to nominate your favorite private biotech for this year’s Endpoints 11
I’ve got a query for you today. Do you know a truly great private biotech out there with outstanding management, super science, ambitious and novel drug development plans, and the resources and backing...
View ArticleClik here to view.
Aerovate’s stock craters after PAH drug fails Phase 2 study
Aerovate Therapeutics’ mid-stage treatment for pulmonary arterial hypertension failed to meaningfully improve patients’ blood pressure compared to placebo across three doses, sending the company’s...
View ArticleClik here to view.
Marinus reports mixed Phase 3 results on IV seizure drug
Marinus Pharmaceuticals reported Monday that its IV drug met only one of two key endpoints in a Phase 3 study for prolonged seizures. In the Phase 3 RAISE study, 96 patients with refractory status...
View Article